November 19, 2021 -- The U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) for booster shots of both the Pfizer-BioNTech COVID-19 vaccine and the Moderna COVID-19 vaccine to include individuals 18 and older.
For the Pfizer-BioNTech vaccine, the booster dose is the same as the doses in the primary series and should be administered at least six months after the primary series was administered, Pfizer said. It was also authorized for use in individuals who completed any other authorized COVID-19 vaccine.
As for the Moderna vaccine, a 50-µg booster dose can be given to all individuals ages 18 and older who have completed primary vaccination with any other authorized or approved COVID-19 vaccine, according to Moderna.
The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices will soon meet to discuss a potential recommendation for the rollout of the Pfizer-BioNTech and Moderna COVID-19 vaccine booster doses.